Dynavax (DVAX) AI Stock Analysis

• Market Cap: $1.17B
• Dividend Yield: N/A
• Average Volume (3M): 1.93M
• Price to Earnings (P/E): 64.5
• Beta (1Y): 0.28
• Revenue Growth: 26.66%
• EPS Growth: -419.55%
• Country: US
• Employees: 405
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.14
• Shares Outstanding: 117,267,480
• 10 Day Avg. Volume: 2,044,077
• 30 Day Avg. Volume: 1,933,626
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.90
• Enterprise Value/Revenue: 3.31
• Enterprise Value/Gross Profit: 4.00
• Enterprise Value/Ebitda: -30.33
• 1Y Price Target: $22.67
• Price Target Upside: 131.80% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 4

• Rating: 54 Neutral
• Price Target: $10.50 ▲(7.36% Upside)

Dynavax's overall stock score reflects a mixed financial performance with profitability challenges, a neutral technical outlook, and a challenging valuation due to a negative P/E ratio. However, the positive earnings call and promising corporate events, such as the shingles vaccine trial results, provide a boost to the score. The company's strategic focus on growth and market expansion is a positive factor, but profitability and valuation concerns weigh on the overall assessment.

Positive Factors

Revenue Growth

The significant revenue growth for HEPLISAV-B reflects strong market demand and effective sales strategies, enhancing long-term revenue stability.

Vaccine Pipeline Progress

Advancements in the vaccine pipeline, particularly the promising shingles vaccine, position Dynavax for future market expansion and diversification.

Strategic Financial Management

The share repurchase program reflects strong financial health and commitment to enhancing shareholder value, supporting long-term investor confidence.

Negative Factors

Profitability Challenges

Negative profitability metrics indicate operational inefficiencies that could hinder long-term financial performance and growth potential.

Increased SG&A Expenses

Rising SG&A expenses may pressure margins and reduce profitability, potentially impacting the company's ability to invest in growth initiatives.

Cash Position Decrease

A decrease in cash reserves limits financial flexibility and could constrain the company's ability to fund R&D and strategic initiatives.

Dynavax Business Overview & Revenue Model

Company Description

Dynavax Technologies Corporation is a biopharmaceutical company focused on developing and commercializing innovative vaccines and immunotherapies. The company is primarily engaged in the research and development of its proprietary toll-like receptor (TLR) platform, which is aimed at enhancing the immune response to infections and diseases. Dynavax's core product is HEPLISAV-B, a hepatitis B vaccine that has received regulatory approvals in various markets, including the United States. The company operates in the biotechnology sector and is dedicated to addressing unmet medical needs through its advanced therapeutic solutions.

How the Company Makes Money

Dynavax generates revenue primarily through the sales of its products, particularly HEPLISAV-B, which has been established as a key revenue stream following its approval and commercialization. The company also engages in collaborations and partnerships with other pharmaceutical companies, which may involve upfront payments, milestone payments, and royalties on future sales of products developed through these collaborations. These strategic partnerships help to bolster Dynavax's financial performance and can provide additional funding for its research and development activities.

Dynavax Financial Statement Overview

Summary

Dynavax is facing significant revenue contraction and net losses, negatively impacting its income statement. The balance sheet shows moderate strength with reasonable leverage, but decreased equity and rising debt are concerning. Cash flow management is adequate, though operational challenges persist.

Income Statement

The income statement shows declining revenue from the previous fiscal year, with a TTM revenue of $294.6M compared to the previous annual revenue of $722.7M. Gross profit margin for the TTM is approximately 82.3%, indicating strong product profitability. However, the net profit margin is negative, at -20.4%, due to a net loss of $60.1M. This reflects challenges in cost management and achieving profitability.

Balance Sheet

The balance sheet is moderately strong, with a debt-to-equity ratio of 0.54, suggesting a balanced use of leverage. The equity ratio stands at 56.1%, highlighting a solid equity base. However, the decline in stockholders' equity and rising total debt indicate potential financial stress.

Cash Flow

Cash flow analysis reveals a positive operating cash flow of $63.6M in the TTM, but free cash flow has decreased compared to the previous year. The operating cash flow to net income ratio is negative, reflecting operational inefficiencies. The free cash flow to net income ratio is positive, suggesting better cash flow management despite net losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	316.27M	277.25M	232.28M	722.68M	439.44M	46.55M
Gross Profit	261.97M	227.80M	182.12M	460.53M	265.87M	32.64M
EBITDA	-34.56M	45.70M	9.67M	307.70M	95.71M	-46.84M
Net Income	-52.73M	27.31M	-6.39M	293.16M	76.71M	-75.24M
Balance Sheet
Total Assets	918.45M	986.26M	997.10M	985.85M	1.04B	353.27M
Cash, Cash Equivalents and Short-Term Investments	613.73M	713.83M	742.30M	624.39M	545.95M	165.04M
Total Debt	285.50M	254.42M	256.91M	258.01M	257.38M	217.85M
Total Liabilities	424.29M	389.46M	375.02M	404.84M	816.87M	294.58M
Stockholders Equity	494.16M	596.80M	622.07M	581.01M	222.37M	58.69M
Cash Flow
Free Cash Flow	66.07M	60.16M	96.46M	55.58M	326.05M	-103.32M
Operating Cash Flow	76.27M	66.51M	100.56M	62.72M	335.53M	-92.25M
Investing Cash Flow	109.60M	-18.04M	-153.93M	-316.00M	14.22M	-26.53M
Financing Cash Flow	-200.20M	-102.02M	1.39M	19.52M	55.78M	109.50M

Dynavax Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 9.78
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DVAX, the sentiment is Neutral. The current price of 9.78 is above the 20-day moving average (MA) of 9.78, below the 50-day MA of 10.41, and below the 200-day MA of 11.50, indicating a neutral trend. The MACD of -0.17 indicates Negative momentum. The RSI at 46.26 is Neutral, neither overbought nor oversold. The STOCH value of 74.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DVAX.

Dynavax Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AMPH	69 Neutral	1.25B	10.05	17.78%	―	1.37%	-18.10%
ANIP	66 Neutral	2.02B	-121.05	-2.53%	―	38.68%	-160.14%
COLL	65 Neutral	1.08B	33.22	15.62%	―	22.61%	-63.00%
PCRX	61 Neutral	1.13B	-9.06	-16.82%	―	2.25%	-301.59%
DVAX	54 Neutral	$1.17B	64.45	-9.28%	―	26.66%	-419.55%
EVO	41 Neutral	1.23B	-7.28	-20.59%	―	-1.03%	8.13%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Dynavax Corporate Events

Dynavax Announces Positive Results for Shingles Vaccine

On August 21, 2025, Dynavax announced positive topline results from Part 1 of its Phase 1/2 clinical trial for Z-1018, a novel shingles vaccine candidate. The trial showed that Z-1018 has comparable immune responses to Shingrix, with a favorable tolerability profile, marking a significant step in Dynavax’s efforts to disrupt the shingles vaccine market. Plans are underway to advance Z-1018 into Part 2 of the trial for adults aged 70 and older, aiming to further de-risk the program before Phase 3 development.

Dynavax Elects Directors and Approves Key Amendments

On April 14, 2025, Dynavax held its Annual Meeting where stockholders elected four Class I directors to serve until the 2028 meeting. The meeting also saw the approval of executive compensation, the ratification of Ernst & Young LLP as the independent auditor, and the amendment of the Certificate of Incorporation to declassify the Board. However, a stockholder proposal to amend the bylaws without stockholder approval was not passed.